Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! Screen on your Watchlists and Portfolios with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Psyence Biomedical Ltd (PBM)

Psyence Biomedical Ltd (PBM)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Market News and Commentary

Save This Psychedelic Stock Watchlist After Trump’s Latest Executive Order

Over the weekend, President Donald Trump pulled out his pen to sign an executive order meant to accelerate research around psychedelic drugs, “including ibogaine compounds,” in the treatment of serious mental illnesses. 

That news has given a major boost to a small, niche corner of the pharmaceuticals market that often faces roadblocks in the form of funding, testing, and regulatory approvals. The AdvisorShares Psychedelics ETF (PSIL) closed up 10%, notching its best day in over a year.

Fundamentals

See More
  • Market Capitalization, $K 7,769
  • Shares Outstanding, K 1,022
  • Annual Sales, $ 0 K
  • Annual Income, $ 1,010 K
  • EBIT $ -3 M
  • EBITDA $ -3 M
  • 60-Month Beta 0.31
  • Price/Sales N/A
  • Price/Cash Flow 0.52
  • Price/Book 0.15

Price Performance

See More
Period Period Low Period High Performance
1-Month
2.26 +400.00%
on 04/02/26
16.96 -33.37%
on 04/20/26
+8.90 (+370.83%)
since 03/20/26
3-Month
1.92 +488.54%
on 02/23/26
16.96 -33.37%
on 04/20/26
+7.11 (+169.85%)
since 01/16/26
52-Week
1.92 +488.54%
on 02/23/26
74.94 -84.92%
on 07/25/25
-10.61 (-48.41%)
since 04/17/25

Most Recent Stories

More News
Save This Psychedelic Stock Watchlist After Trump’s Latest Executive Order

From manufacturers to high volatility biotechs, these are the mind-bending med stocks our Senior Market Strategist is watching now.

CMPS : 9.46 (+42.04%)
PSIL : 20.72 (+10.48%)
ATAI : 4.90 (+21.59%)
JAZZ : 202.56 (-0.42%)
PBM : 11.30 (+48.68%)
Psyence BioMed Positioned as World's only Licensed Pharmaceutical Grade Ibogaine Supplier at Source

NEW YORK, April 20, 2026 (GLOBE NEWSWIRE) -- Psyence Biomedical Ltd. (Nasdaq: PBM) (“Psyence BioMed” or the “Company”), a clinical-stage biopharmaceutical company advancing nature-derived psychedelic...

PBM : 11.30 (+48.68%)
Psyence BioMed Welcomes U.S. Executive Action to Advance Research into Ibogaine

NEW YORK, April 17, 2026 (GLOBE NEWSWIRE) -- Psyence Biomedical Ltd. (Nasdaq: PBM) (“Psyence BioMed” or the “Company”), a clinical-stage biopharmaceutical company advancing nature-derived psilocybin...

PBM : 11.30 (+48.68%)
Psyence BioMed Expands Australian Clinical Site Network to Five Sites, Advancing NPX-5–Supported Clinical Activities

NEW YORK, April 08, 2026 (GLOBE NEWSWIRE) -- Psyence Biomedical Ltd. (Nasdaq: PBM) (“Psyence BioMed” or the “Company”), a biopharmaceutical company advancing nature-derived psilocybin and ibogaine...

PBM : 11.30 (+48.68%)
Corporate Update: Psyence BioMed Advances Vertically Integrated Pharmaceutical Platform Following PsyLabs Export Milestone

NEW YORK, March 11, 2026 (GLOBE NEWSWIRE) -- Psyence Biomedical Ltd. (Nasdaq: PBM) (“Psyence BioMed” or the “Company”) today reinforced how its strategic investment in PsyLabs strengthens its...

PBM : 11.30 (+48.68%)
Psyence BioMed Announces Export of GMP-Manufactured Natural Psilocybin (NPX-5) to Australia for Ongoing Phase IIb Clinical Trial

NEW YORK, March 03, 2026 (GLOBE NEWSWIRE) -- Psyence Biomedical Ltd. (Nasdaq: PBM) (“Psyence BioMed” or the “Company”), a biopharmaceutical company advancing nature-derived psilocybin and ibogaine...

PBM : 11.30 (+48.68%)
Psyence BioMed Announces Exercise of Put Option by PsyLabs and Strategic Equity Investment

NEW YORK, Feb. 20, 2026 (GLOBE NEWSWIRE) -- Psyence Biomedical Ltd. (Nasdaq: PBM) (“ Psyence BioMed ” or the “ Company ”), a biopharmaceutical company advancing nature-derived psilocybin and...

PBM : 11.30 (+48.68%)
Psyence BioMed Announces Results of Annual and Special Meeting of Shareholders

NEW YORK, Feb. 17, 2026 (GLOBE NEWSWIRE) -- Psyence Biomedical Ltd. (Nasdaq: PBM) (“ Psyence BioMed ” or the “ Company ”), a biopharmaceutical company advancing nature-derived psilocybin and...

PBM : 11.30 (+48.68%)
Psyence BioMed Approves Put Option Agreement with PsyLabs to Secure Strategic Supply and Strengthen Commercialization Pathway

NEW YORK, Feb. 13, 2026 (GLOBE NEWSWIRE) -- Psyence Biomedical Ltd. (Nasdaq: PBM) (“ Psyence BioMed ” or the “ Company ”), a biopharmaceutical company advancing nature-derived psilocybin and...

PBM : 11.30 (+48.68%)
Psyence BioMed Announces Settlement of Shareholder Litigation

NEW YORK, Feb. 11, 2026 (GLOBE NEWSWIRE) -- Psyence Biomedical Ltd. (Nasdaq: PBM) (" Psyence BioMed " or the " Company ") today announced that it has entered into a settlement agreement to resolve a...

PBM : 11.30 (+48.68%)

Business Summary

Psyence Biomed is a life science biotechnology company which focus on natural psychedelics. The company's operating divisions include Psyence Production, Psyence Therapeutics and Psyence Function which operates in Canada, the United Kingdom, Southern Africa, Australia and a presence in the United States....

See More

Key Turning Points

3rd Resistance Point 21.05
2nd Resistance Point 19.01
1st Resistance Point 15.15
Last Price 11.30
1st Support Level 9.25
2nd Support Level 7.21
3rd Support Level 3.35

See More

52-Week High 74.94
Fibonacci 61.8% 47.04
Fibonacci 50% 38.43
Fibonacci 38.2% 29.81
Last Price 11.30
52-Week Low 1.92

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.